Brief: Bcal Diagnostics Posts FY Net Loss Attributable A$5.1 Million
30/08/2023 01:26
Aug 30 (Reuters) - BCAL Diagnostics BDX.AX :
* FY NET LOSS ATTRIBUTABLE A$5.1 MILLION VERSUS LOSS OF
A$3.4
MILLION
* FY REVENUE FROM ORDINARY ACTIVITIES A$2.9 MILLION VERSUS
A$718,669
Source text for Eikon: ID:nASX5kX8sC
Further company coverage: BDX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BCAL Diagnostics
See all newsAustralia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: BCAL To Acquire Shares In Genetic Signatures